Recent News

• 05.30.2026 - ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01
• 05.30.2026 - ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
• 05.30.2026 - ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab

Recent Filings

• 05.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - 144 Report of proposed sale of securities
• 05.21.2026 - 144 Report of proposed sale of securities
• 05.21.2026 - EX-99.1 EX-99.1
• 05.21.2026 - 8-K Current report
• 05.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.18.2026 - 144 Report of proposed sale of securities
• 05.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - 144 Report of proposed sale of securities